var config = {
    "presentation": "SPR_TRIUMEQ_2016_MAIN",       
    "homepage": "SPR_TRIUMEQ_2016_01",                   
    "menuPresentation": "",    
    "menu": "",                      
    "referencesPresentation": "", 
    "references": "",     
    "piPresentation": "",
    "pi": "",
    "veevaSwipe": "0",
    "mtgskAnimations": "1",
    "mtgskPortrait": "0",
    "referencesAll": [
        "Adapted from Walmsley S, et al. J Acquir Immune Defic Syndr 2015;70:515–9",
        "Adapted from Pappa K, et al. ICAAC 2014. Oral H-647a",
        "Adapted from Walmsley S, et al. N Engl J Med 2013;369:1807–18",
        "Triumeq Summary of Product Characteristics, September 2016",
        "Raffi F, et al. Lancet Infect Dis 2013;13:927–35",
        "Molina JM, et al. Lancet HIV 2015;2:e127–36",
        "Cohen CJ, et al. AIDS 2013;27:939–50",
        "Zolopa A, et al. J Acquir Immune Defic Syndr 2013;63:96–100",
        "Rockstroh JK, et al. J Acquir Immune Defic Syndr 2013;62:483–6",
        "Wohl D, et al. EACS 2015. Poster LBBPD1/1",
        "Atripla Summary of Product Characteristics, September 2016",
        "Stribild Summary of Product Characteristics, September 2016",
        "Eviplera Summary of Product Characteristics, July 2016",
        "Genvoya Summary of Product Characteristics, August 2016",
        "Adapted from Orrell C, et al. AIDS 2016. Oral THAB0205LB",
        "Adapted from Squires K, et al. Lancet HIV 2016;3:3410–20"
    ],
    "pageReferencesAll": [
        [],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16],
        [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]
    ],
    "pagesAll": [
        "SPR_TRIUMEQ_2016_01",
        "SPR_TRIUMEQ_2016_02",
        "SPR_TRIUMEQ_2016_03",
        "SPR_TRIUMEQ_2016_04",
		"SPR_TRIUMEQ_2016_05",
		"SPR_TRIUMEQ_2016_06",
		"SPR_TRIUMEQ_2016_07",
        "SPR_TRIUMEQ_2016_08",
        "SPR_TRIUMEQ_2016_09",
        "SPR_TRIUMEQ_2016_10",
        "SPR_TRIUMEQ_2016_11",
        "SPR_TRIUMEQ_2016_12",
		"SPR_TRIUMEQ_2016_13"
    ],
	"pagesTitles": [
        "TRIUMEQ* COMPONENTS (ABC/3TC/DTG) DEMONSTRATE SUPERIOR EFFICACY VS ATRIPLA AT WEEKS 48, 96 AND 144",
        "TRIUMEQ* DEMONSTRATES A FASTER MEDIAN TIME TO VIRAL SUPPRESSION VS ATRIPLA",
        "TRIUMEQ* IS EFFECTIVE IN PATIENTS WITH HIGH AND LOW BASELINE VIRAL LOAD",
        "NO TREATMENT-EMERGENT RESISTANCE WITH DOLUTEGRAVIR-CONTAINING REGIMENS IN TREATMENT-NAÏVE PATIENTS THROUGH 96 WEEKS",
		"DOLUTEGRAVIR IS GENERALLY WELL TOLERATED THROUGH 96 WEEKS",
		"TRIUMEQ* MAKES DOSING AND ADMINISTRATION CONVENIENT FOR YOUR PATIENTS WITH HIV-1",
		"TRIUMEQ* IS SUPERIOR‡ TO ATV/r + TDF/FTC IN TREATMENT-NAÏVE WOMEN AT 48 WEEKS IN ARIA15",
		"EVG/c/FTC/TDF DEMONSTRATES SUPERIOR* EFFICACY IN WOMEN AT 48 WEEKS IN WAVES16",
        "NO TREATMENT-EMERGENT RESISTANCE WITH TRIUMEQ* IN TREATMENT-NAÏVE WOMEN THROUGH 48 WEEKS IN ARIA15",
        "NO TREATMENT-EMERGENT RESISTANCE WITH EVG/c/FTC/TDF IN TREATMENT-NAÏVE WOMEN THROUGH 48 WEEKS IN WAVES16",
        "TRIUMEQ* IS GENERALLY WELL TOLERATED IN WOMEN THROUGH 48 WEEKS IN ARIA15",
        "EVG/c/FTC/TDF IS GENERALLY WELL TOLERATED IN TREATMENTNAÏVE WOMEN THROUGH 48 WEEKS IN WAVES16"
    ]
};